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positioning methods. The doses received by 20%, 40% and 50% 
volume of bladder were compared to those of the original 
treatment plans. 
Results: Based on contours from CBCT images, for bony 
anatomy positioning method the delivered bladder doses 
were on average 591.7 cGy (± 276), 413.6 cGy (± 178), 367.4 
cGy (± 93) lower than the planned dose for D20%, D40%, D50% 
respectively. For fiducial positioning method, they were 
141.2 cGy (± 84), 82.2 cGy (± 61), 67.3 cGy (± 47) lower than 
the planned dose respectively. The dose difference between 
planned and delivered dose shows that the greatest variation 
depending on the bladder filling among the fractions. 
Although, significant differences in bladder volumes and 
subsequent increases in dose were observed in two out of ten 
patients, the bladder doses are still within the acceptance 
criteria. Results indicate a wide range in bladder doses 
throughout treatment, which partly depends on the methods 
used for patient positioning. Of the two patient positioning 
methods evaluated, the least amount of bladder dose 
variability, is seen when target localization was made using 
intraprostatic fiducials. 
Conclusions: Large interfraction variations in bladder filling 
hamper accurate radiotherapy of prostate cancer. Although 
the reproducibility of bladder filling during treatment is low, 
since the estimated mean bladder volume is generally larger 
when compared with the value at the planning CT scan, the 
bladder doses are within the tolerance limits. 
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Purpose/Objective: Late rectal toxicity is one of the most 
important negative consequencies of radiation therapy in 
patients with prostatic carcinoma (CAP). In a previous study 
we observed a significant correlation between proctoscopy 
outcome one year after RT and late rectal toxicity during the 
follow-up. Therefore we proposed early proctoscopy as a 
surrogate end-point for late rectal toxicity. Aim of this study 
was to investigate predictive factors of late rectal toxicity by 
proctoscopy. 
Materials and Methods: The analysis included all patients 
who underwent proctoscopy one year after the end of 
radiation therapy. Proctoscopy was performed by the same 
operators, using Wachter score. The following parameters 
were analyzed as potential predictive factors: RT dose, 
fractionation, pelvic lymph nodes irradiation, previous 
prostatectomy, timing and type of hormone therapy. 
Statistical analysis was performed using the chi-square test 
(univariate analysis) and logistic model (multivariate 
analysis). 
Results: In this analysis 157 patients with non metastatic CAP 
treated with curative and adjuvant RT were included. 
The results are shown in the table below. 
 
Conclusions: In a proctoscopy evaluation of radiation-
induced rectal toxicity only patients who underwent adjuvant 
hormonal therapy based on LH-RH- analogues, showed a 
trend to a higher risk of toxicity. The lack of correlation with 
other clinical parameters can be partially explained by the 
use of SIB-based modulated techniques (IMR-VMAT) in 
patients treated with hypofractionated RT. 
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Purpose/Objective: MR imaging following needle 
implantation in high dose rate brachytherapy (HDR BT) 
provide more anatomical details for improved definition of 
the prostate gland, organs at risk, and needles. The purpose 
of this study was to evaluate the introduction of MRI guided 
HDR BT, including time consumption, dose volume 
parameters, and changes over time.  
Materials and Methods: A team of radiation oncologists, 
physicists, radiologists, and nurses was trained to perform 
MRI guided HDR BT. Between September 2012 and November 
2014, 42 consecutive high risk prostate cancer patients 
received two times HDR BT of each 8.5 Gy after EBRT. Time 
was recorded for initiation of anaesthesia, end of ultrasound 
guided needle implantation, MR scan, and HDR BT delivery. 
We defined implantation time as duration from initiation of 
anaesthesia to end of needle implantation, and total 
procedure time as duration from initiation of anaesthesia to 
end of HDR BT delivery. Dose volume parameters were 
retrieved from the dose planning system. 
Results: Implantation time was reduced from an initial level 
of ~4.5 hours min to ~2.5 hours at ~800 days from 
introduction. Implantation time at the second HDR BT 
procedure was in average 12 min faster than the first. Total 
procedure time was reduced from an initial level of ~10 hours 
min to ~5 hours min at ~800 days from introduction. Total 
procedure time of the second HDR BT was in average 17 min 
faster than the first. Estimated extra time consumption of 
the post implant MRI was median 66 min (range 26-195 min). 
